Damage of a single organ accounts for the majority of human illnesses with liver disease affecting over 500 million people and accounting for over 2 million annual deaths worldwide

Active Cooperative Agreement Awarded

Award ID
D25AC00322
Recipient
Awarding agency
Obligated
$17,815,284

Award facts

Completion date 38% complete
Place of performance
Massachusetts, USA

Award details come from USAspending.gov.

Description

At this time the only curative therapy is orthotopic transplant of a donor liver. However due to the severe shortage of donor organs transplants are limited to only a fraction of the population who might benefit from liver replacement therapy largely due to the low availability and high cost and complex surgery and lifelong immunosuppression requirements. As such millions of patients are left without an accessible solution. The implant team aims to address this challenge by establishing the first off the shelf engineered product to address liver failure. The solution is built on several next generation technologies including tools to drive inducible pluripotent stem cell differentiation into all required cells of the liver and immune engineering to allow allogeneic cells to evade immune rejection and bioreactors to facilitate manufacturing and maturation of cells and engineered tissues at low cost and simple biofabrication technologies to build clinical scale constructs. Implant will generate a universal and transplant ready graft that cooperates with the native liver to maintain homeostasis and sometimes even leading to its recovery and regeneration through metabolic offloading and bringing hope to millions of patients for whom the current liver transplant paradigm fails. The project will culminate with a GMP manufactured biobank of cells and universal liver tissues with effectiveness demonstrated in humanized mice and humanized PIG models to support technology translation towards clinical trials. Beyond implant we expect the path to regulatory approval to progress through a narrow indication ultimately into serving the millions of patients with serious liver diseases. Overall this project aims to provide a solution that will revolutionize the treatment of liver disease and serving all populations many of whom are currently excluded from transplant.

Subawards

Subrecipient Amount Awarded
The Trustees Of Columbia University In The City Of New York TA2 will develop bioreactors for GLP (Phase I) and GMP (Phase II) compliant manufacturing, maturation and functional evaluation of liver cell populations,… $1,923,465
The Trustees Of Columbia University In The City Of New York We will assess the survival and immunogenicity of edited iPSCs in human immune system (HIS) mice. Specifically, we will leverage the Hu/Hu mouse developed by… $490,218
Massachusetts Institute Of Technology In collaboration with team members from Wyss Institute, University of Colorado, and Columbia University, the Weiss lab will leverage our synthetic biology… $828,818
The Regents Of The University Of Colorado The specific work to be completed at CU includes: i) the fabrication of hydrogel microparticles and their culture with liver organoids to fabricate liver… $1,094,807

Quick answers

Who received award D25AC00322?

D25AC00322 was awarded to President And Fellows Of Harvard College by Interior Business Center (Office of Policy Management and Budget) on September 25, 2025.

How much is award D25AC00322 worth?

$17,815,284 has been obligated on D25AC00322.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award